Zymeworks (ZYME)
NASDAQ:ZYME
Want to see ZYME full AI Analyst Report?
ZYME Stock Chart & Stats
$27.80
-$0.11(-0.77%)
At close: 4:00 PM EST
$27.80
-$0.11(-0.77%)
Day’s Range― - ―
52-Week Range$11.51 - $29.75
Previous CloseN/A
Volume35.38K
Average Volume (3M)690.95K
Market Cap
$1.71B
Enterprise Value-$225.39B
Total Cash (Recent Filing)$364.73M
Total Debt (Recent Filing)$17.04M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Jul 30, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding73,023,060
10 Day Avg. Volume749,826
30 Day Avg. Volume690,950
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap-131.71
Enterprise Value/Revenue-2.77K
Enterprise Value/Gross Profit-2.94K
Enterprise Value/Ebitda2.03K
Forecast
1Y Price Target
$37.38Price Target Upside34.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.57
Revenue Forecast (FY)$309.60M
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline Efficacy (ZW191)Robust early efficacy signals in heavily pretreated ovarian and endometrial cohorts demonstrate Zymeworks' ability to generate clinically meaningful ADC activity. Durable response rates support the asset's standalone commercial potential or attractive partnering value, improving long‑term revenue optionality beyond near‑term milestone timing.
Proprietary ADC / Pan‑RAS PlatformA differentiated ADC platform (DAR‑8 format, novel TOPA payloads) that produced multiple preclinical candidates and favorable NHP tolerability increases the firm's ability to replenish the pipeline. Platform-level R&D creates repeatable product opportunities, strengthens licensing leverage, and supports long-term scientific differentiation.
Improved Liquidity Via Royalty Monetization And Cash BalanceNon‑dilutive royalty monetization plus a materially higher cash balance meaningfully extend runway and reduce immediate funding pressure. This strengthens strategic optionality for R&D, partnerships or M&A and supports disciplined capital allocation, provided milestone and royalty assumptions hold over the medium term.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow indicates the core business is cash‑consuming and reliant on external funding or milestone monetization. Over the next several quarters this elevates financing risk, constrains investment flexibility, and increases the company's dependence on milestone timing or strategic transactions to avoid dilution.
Dependence On Partner Milestones And RoyaltiesA business model reliant on external approvals, partner commercialization choices and royalties transfers material cash‑flow control to third parties. Delays, pricing pressure outside the U.S., or partner execution shortfalls can sharply reduce expected inflows, making the company's funding plan and long‑term growth harder to secure independently.
Revenue Volatility And Widening LossesLarge year‑over‑year revenue swings and expanding GAAP losses signal inconsistent commercial and milestone timing, undermining predictability. Persistent losses reduce retained earnings and ROE, pressuring the balance sheet over time and increasing the need for milestone success or external capital to sustain R&D and development timelines.
Zymeworks News
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $11.51 and its highest was $29.75 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $1.71B.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Jul 30, 2026 which is in 50 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on May 07, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.297 by -$0.293.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.38.
How many shares outstanding does Zymeworks have?
Zymeworks has 73,023,060 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.297. Following the earnings report the stock price went down -10.188%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.38 (34.44% Upside)
$37.38 (34.44% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 581.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.92%
12-Months-Change
Fundamentals
Return on Equity
-0.25%
Trailing 12-Months
Asset Growth
12.38%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$37.38
▲(34.44% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
32.73% Insiders
8.15% Mutual Funds
5.47% Other Institutional Investors
40.50% Public Companies and
Individual Investors